Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Performance of Indexed and Nonindexed Estimated GFR

    Publikation: Bidrag til tidsskriftLetterpeer review

  2. Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder

    Publikation: Bidrag til tidsskriftLederpeer review

  3. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Katherine R Tuttle
  • Frank C Brosius
  • Matthew A Cavender
  • Paola Fioretto
  • Kevin J Fowler
  • Hiddo J L Heerspink
  • Tom Manley
  • Darren K McGuire
  • Mark E Molitch
  • Amy K Mottl
  • Leigh Perreault
  • Sylvia E Rosas
  • Peter Rossing
  • Laura Sola
  • Volker Vallon
  • Christoph Wanner
  • Vlado Perkovic
Vis graf over relationer

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption in the proximal tubule. In clinical trials designed to demonstrate the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks for secondary kidney disease end points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular filtration rate decline, kidney failure, or death), along with reductions in CVD events, were observed. In patients with CKD, the kidney and CVD benefits of canagliflozin were established by the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial in patients with T2DM, urinary albumin-creatinine ratio>300mg/g, and estimated glomerular filtration rate of 30 to<90mL/min/1.73m2. To clarify and support the role of SGLT2 inhibitors for treatment of T2DM and CKD, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts. They discussed the current state of knowledge and unanswered questions to propose therapeutic approaches and delineate future research. SGLT2 inhibitors improve glomerular hemodynamic function and are thought to ameliorate other local and systemic mechanisms involved in the pathogenesis of CKD and CVD. SGLT2 inhibitors should be used when possible by people with T2DM to reduce risks for CKD and CVD in alignment with the clinical trial entry criteria. Important risks of SGLT2 inhibitors include euglycemic ketoacidosis, genital mycotic infections, and volume depletion. Careful consideration should be given to the balance of benefits and harms of SGLT2 inhibitors and risk mitigation strategies. Effective implementation strategies are needed to achieve widespread use of these life-saving medications.

TidsskriftAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
Udgave nummer1
Sider (fra-til)94-109
Antal sider16
StatusUdgivet - jan. 2021

Bibliografisk note

Copyright © 2020 The National Kidney Foundation, Inc and American Diabetes Association. Published by Elsevier Inc. All rights reserved.

ID: 61261484